{"id":"NCT02163824","sponsor":"Kala Pharmaceuticals, Inc.","briefTitle":"Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation","officialTitle":"A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2014-06-16","resultsPosted":"2020-12-22","lastUpdate":"2021-01-29"},"enrollment":380,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ocular Infections, Irritations and Inflammations"],"interventions":[{"type":"DRUG","name":"KPI-121 0.25%","otherNames":["KPI-121 0.25% Ophthalmic Suspension","Loteprednol etabonate 0.25%"]},{"type":"DRUG","name":"KPI-121 1.0%","otherNames":["KPI-121 1.0% Ophthalmic Suspension","Loteprednol etabonate 1.0%"]},{"type":"DRUG","name":"Vehicle of KPI-121 0.25%","otherNames":["Vehicle of KPI-121 0.25% Ophthalmic Suspension"]},{"type":"DRUG","name":"Vehicle of KPI-121 1.0%","otherNames":["Vehicle of KPI-121 1.0% Ophthalmic Suspension"]}],"arms":[{"label":"KPI-121 0.25% QID","type":"ACTIVE_COMPARATOR"},{"label":"KPI-121 1.0% BID","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle of KPI-121 0.25%","type":"PLACEBO_COMPARATOR"},{"label":"Vehicle of KPI-121 1.0%","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery. The efficacy and safety of two different concentrations and two different dosing regimens of KPI-121 are also being assessed.","primaryOutcome":{"measure":"Resolution of Anterior Chamber Cells","timeFrame":"Visit 5 (postoperative day 8) and Visit 6 (postoperative day 15)","effectByArm":[{"arm":"KPI-121 0.25% QID","deltaMin":48,"sd":null},{"arm":"KPI-121 1.0% BID","deltaMin":39,"sd":null},{"arm":"Vehicle of KPI-121","deltaMin":19,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":".0024"},{"comp":"OG000 vs OG002","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":23,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":129},"commonTop":["eye pain","photophobia","eye inflammation","headache","corneal oedema"]}}